Russell Barton
Geschäftsführer bei ACUMEN PHARMACEUTICALS, INC.
Vermögen: 284 789 $ am 31.05.2024
Aktive Positionen von Russell Barton
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ACUMEN PHARMACEUTICALS, INC. | Geschäftsführer | 01.04.2019 | - |
AgeneBio, Inc.
AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | Technik-/Wissenschafts-/F&E-Leiter | 01.10.2019 | - |
Pharma Sagacity Consulting LLC | Präsident | 01.01.2018 | - |
Karriereverlauf von Russell Barton
Ehemalige bekannte Positionen von Russell Barton
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ELI LILLY AND COMPANY | Geschäftsführer | - | - |
Ausbildung von Russell Barton
Illinois State University | Undergraduate Degree |
Purdue University | Graduate Degree |
Statistik
International
Vereinigte Staaten | 7 |
Operativ
Chief Operating Officer | 2 |
Undergraduate Degree | 1 |
Graduate Degree | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
ACUMEN PHARMACEUTICALS, INC. | Health Technology |
ELI LILLY AND COMPANY | Health Technology |
Private Unternehmen | 2 |
---|---|
AgeneBio, Inc.
AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | Health Technology |
Pharma Sagacity Consulting LLC |
- Börse
- Insiders
- Russell Barton
- Erfahrung